Hair Loss Drugs: The Benefits and Risks Worth Weighing, Per Research

Last week we covered what food can do for thinning hair — and the honest answer was that food fixes the deficiencies holding your hair back, but it can’t override the hormone signal telling follicles to shrink. That’s where drugs enter. If you’ve read the evidence on hair growth foods and your ferritin is fine, protein is adequate, and the shedding continues, the next decision is pharmacological — and it deserves more thought than the Instagram ads give it.

Every hair loss drug works by pushing back on the same process: follicular miniaturization driven by dihydrotestosterone, or DHT. The drugs don’t regrow dead follicles. They rescue shrinking ones and hold the line. Which drug, at what risk, is where the weighing starts.

Finasteride: the one with the loudest debate

Finasteride blocks the 5-alpha-reductase enzyme that converts testosterone into DHT, cutting DHT levels roughly 65–70% at the standard 1 mg dose. The efficacy record is strong — a review of pattern hair loss treatments found oral finasteride consistently outperforms placebo in preserving and partially regrowing hair (York et al., Expert Opin Pharmacother, 2020 — https://pubmed.ncbi.nlm.nih.gov/32066284/), and a head-to-head comparison put it among the most effective options available (Gupta et al., J Dermatolog Treat, 2022 — https://pubmed.ncbi.nlm.nih.gov/35920739/).

The risk conversation centers on sexual side effects — lowered libido, erectile dysfunction — reported in a small percentage of users, usually within the first year. The medical literature pegs the rate low, and symptoms typically reverse on discontinuation, but a stubborn subset of patients reports persistent effects after stopping. That persistence is genuinely debated: large analyses find no difference from placebo at population level, while patient communities insist the post-finasteride syndrome is real. Both things can be true at different rates — a rare but real experience can hide inside a null population average. If you’re weighing this drug, the honest framing is: most people tolerate it without issue, some don’t, and you can’t know in advance which group you’re in.

For women of reproductive age, there’s a harder line. Finasteride is a teratogen — it can feminize a male fetus — and it’s generally not recommended for premenopausal women at all, partly for that reason and partly because the efficacy data in premenopausal women is thin. Postmenopausal data exists but is mixed. If your cycle is still showing up, this is usually not your drug.

Minoxidil: low risk, real commitment

Minoxidil doesn’t touch hormones. It opens potassium channels and improves blood flow to the follicle, pushing hairs into a longer growth phase — which is why it works on essentially anyone’s scalp, regardless of the DHT story. Topical 5% is the standard; the newer twist is low-dose oral minoxidil, which dermatology has adopted enthusiastically. A multicenter study of 1,404 patients on low-dose oral minoxidil found hypertrichosis (unwanted hair growth, usually on the face) as the main side effect in a meaningful minority, with more serious events rare (Vañó-Galván et al., J Am Acad Dermatol, 2021 — https://pubmed.ncbi.nlm.nih.gov/33639244/). A 2024 randomized trial found oral minoxidil beat topical on effectiveness, at the cost of body-wide hair growth risk rather than scalp-local (Penha et al., JAMA Dermatol, 2024 — https://pubmed.ncbi.nlm.nih.gov/38598226/).

The catch with minoxidil isn’t danger — it’s the shed. When you start, resting hairs get pushed out to make room for new growth, and weeks two through eight can look like the drug is making things worse. Most quitters quit here, right before the payoff. The other catch is permanence of commitment: stop taking it and everything it held in place falls out within months. A 2026 review frames it plainly: effective, generally well-tolerated, but a lifetime therapy (Ong et al., Am J Clin Dermatol, 2026 — https://pubmed.ncbi.nlm.nih.gov/40639879/).

Dutasteride and spironolactone: the stronger, riskier, or off-label options

Dutasteride blocks the same enzyme as finasteride but harder — two enzyme isoforms instead of one, cutting DHT over 90%. The comparison data shows it edges out finasteride on regrowth (Gupta et al., 2022 — https://pubmed.ncbi.nlm.nih.gov/35920739/). The trade is proportional: more DHT suppression, more side-effect exposure of the same kinds, and the same teratogen warning. In several countries it’s approved for hair loss; in the US it’s off-label, which means your prescriber is making a judgment call.

Spironolactone is the women’s option. It’s an old blood-pressure drug with anti-androgen effects, prescribed off-label for female pattern hair loss constantly. A 2025 randomized placebo-controlled pilot in premenopausal women found meaningful improvement in hair density over placebo, with tolerable side effects at the doses used (Werachattawatchai et al., Int J Womens Dermatol, 2025 — https://pubmed.ncbi.nlm.nih.gov/40978669/). The risks that matter: it raises potassium, so it interacts with salt substitutes and magnesium supplements, it’s famously contraceptive-unfriendly — adequate birth control is mandatory because of anti-androgen effects on male fetal development — and it can cause irregular cycles, which many perimenopausal women don’t need help with.

A broader treatment review sums up the shared reality: efficacy exists across all of these, but compliance, cost, and side-effect trade-offs drive most real-world discontinuation (Nestor et al., J Cosmet Dermatol, 2021 — https://pubmed.ncbi.nlm.nih.gov/34741573/).

What to do with this

First, get a diagnosis before a drug. Hair loss has several causes — thyroid, iron, stress shedding, pattern loss — and drugs aimed at DHT do nothing for the others. The supplements evidence review covers the deficiency side; a dermatologist visit covers the rest. Second, if you start one of these, give it the full timeline — six to twelve months for the honest verdict, and budget for the early shed. Third, don’t stack experiments: one intervention at a time, so you know what’s working.

If topical minoxidil is the route, the 5% minoxidil foam with biotin is a widely available option, and this 5% serum multipack works out cheaper per month for the long haul. Both are no-prescription, lowest-risk entry points.

If you’re going oral, do it with a prescriber monitoring you — oral minoxidil and the 5-AR inhibitors are real medications with real interactions, not cosmetics.

What we still don’t know

The unresolved question is the one finasteride haters and defenders keep talking past each other on: whether post-finasteride syndrome exists as a persistent biological state, and if so, in whom. Population studies can’t settle a condition that’s rare, self-reported, and hard to objectify — and the trials that could are nobody’s commercial priority. Until then, the risk you’re weighing is partly a matter of whose data you trust.

Save this for the dermatologist appointment you keep putting off.